- AdventHealth
Rajan Wadhawan, MD, was appointed by the Florida Speaker of the House of Representatives to serve as one of the inaugural council members the state of Florida’s Rare Disease Advisory Council (RDAC).
Board certified in pediatrics and neonatal perinatal medicine, Wadhawan currently serves as the senior executive officer of AdventHealth for Children and AdventHealth for Women.
Nearly 1 in 10 Americans estimated to be living with a rare disease and there are over 7,000 known unique rare diseases. Florida established the RDAC in June 2021 to assist the Department of Health in providing recommendations to improve health outcomes for individuals residing in the state who have a rare disease.
As one of 20 representatives on Florida’s newly created RDAC, Wadhawan and his colleagues will work to improve health outcomes for those with a rare disease by making recommendations to state leaders on critical issues, including the need for increased awareness, diagnostic tools and access to affordable treatments and cures.
“The formation of a council like this, which is comprised of individuals from different disciplines, with their own expertise and perspective of this area, will help advance the agenda for these patients at the state level,” Wadhawan said. “The combined expertise of the members of this council, who are all volunteering their time for this cause, will work with Florida’s government officials to remove common obstacles that rare disease patients face, such as delays in diagnosis, misdiagnosis, lack of treatment options, high out-of-pocket costs and limited access to medical specialists.”
All council members are appointed positions with a four-year term. The RDAC is composed of 10 members appointed by the Governor, five members appointed by the Florida President of the Senate and five members appointed by the Speaker of the Florida House of Representatives. Working together, this council will help shape the state’s medical landscape for the care of individuals with rare diseases.
The National Organization for Rare Disease (NORD) launched Project RDAC in November 2020 to help address barriers that prevent individuals living with rare diseases from obtaining proper treatment and care for their conditions.
In June, Florida became the 19th state to pass legislation creating an RDAC, with Senate Bill 272 and House Bill 1373 being signed into law by Governor Ron DeSantis. Two more states have since followed in establishing their own rare disease advisory councils, bringing the total number of states with an RDAC to 21.
Wadhawan attended medical school and residency at Government Medical College in Amritsar, India. He completed his fellowship at Women and Infants Hospital in Providence, Rhode Island. He also earned a master’s degree in medical management from Carnegie Mellon University and is board certified in medical management by the Certifying Commission for Medical Management as a Certified Physician Executive (CPE). Additionally, he’s a member of the American Board of Pediatrics Sub-Board of Neonatal-Perinatal Medicine.
Wadhawan will serve in this statewide post through September 2025.
Recent News
AdventHealth Cancer Institute Advances the Use of CAR T-Cell Therapy for Multiple Myeloma
CAR-T therapies have emerged as new treatment options for certain types of cancer through a one-time infusion that can lead to long-lasting remission.
AdventHealth Graduate Medical Education Program Celebrates 50 Years
Growing from a family practice residency to 24 accredited programs, AdventHealth’s Graduate Medical Education (GME) program celebrates 50 years.
New Clinical Trial Explores Digital Intervention for Apathy in Late-life Depression
Afflicting 30-50% of patients with late-life depression, apathy is a challenging psychiatric syndrome in older adulthood that can result in lack of motivation leading to poor self-care, physical...
AdventHealth Performs Central Florida’s First Liver Transplant for Unresectable Colorectal Liver Metastases
In June 2025, AdventHealth Abdominal Transplant Surgeon and Surgical Oncologist Ryan Day, MD, worked with a multidisciplinary team to perform Central Florida’s first liver transplant for unresectable...
AdventHealth Neuroscience Institute First in Florida to be Recognized as a GammaTile Center of Excellence
GammaTile is the first and only tile-based radiation therapy for the treatment of
operable brain tumors. The AdventHealth Neuroscience Institute began performing GammaTile procedures in 2021 and was...
An AdventHealth Collaboration Explores the Impact of Microgravity and Electrical Stimulation on Muscle Cell Health in Space
Using a muscle lab-on-chip model aboard the International Space Station (ISS), AdventHealth Translational Research Institute’s Dr. Paul Coen has been working with a multidisciplinary team from the...
AdventHealth Neuroscience Institute Among First in U.S. to Offer Phase IIa Clinical Trial of Troculeucel for Moderate Alzheimer’s Disease
While most clinical trials for Alzheimer’s disease have focused on patients with early or mild cognitive impairment, roughly 30% of those with Alzheimer’s have moderate stage disease for which there...
AdventHealth Translational Research Institute Selected as Clinical Site for National Study of Muscle, Mobility and Aging (SOMMA)
Under the leadership of Scientific Director and Principal Investigator Bret H. Goodpaster, PhD, the AdventHealth Translational Research Institute (TRI) is now enrolling men and women 70 years of age...
AdventHealth Neuroscience Institute Administers First Dose of Investigative NK Cell Therapy to Person with Alzheimer’s Disease
Under a single compassionate use Investigational New Drug (IND) authorization cleared by the U.S. Food and Drug Administration (FDA), the AdventHealth Neuroscience Institute worked with NKGen Biotech...
New Study Published in the New England Journal of Medicine Shows the Addition of Regional Nodal Irradiation Does Not Decrease Rate of Invasive Breast Cancer Recurrence in Patients with Negative Axillary Nodes Following Neoadjuvant Chemotherapy
Findings of the phase III, multicenter, randomized NSABP B-51-RTOG 1304 clinical trial were recently published in the New England Journal of Medicine with AdventHealth Cancer Institute’s Dr. Mamounas...
AdventHealth Study Exploring the Use of MR-Guided Focused Ultrasound (MRgFUS) to Disrupt the Blood-Brain Barrier for Treatment of Alzheimer’s Disease
Under the leadership of Dr. Valeria Baldivieso and Dr. Chandan Reddy, the AdventHealth Research Institute is the first and only site in Orlando offering the Exablate Blood-Brain Barrier (BBB)...
AdventHealth Research Institute Offers Phase II Clinical Trial of Etanercept for Treatment of Blast-Induced Tinnitus
Approximately 1 billion people throughout the world suffer from tinnitus (ringing in the ears), and it is the number one disability of those who serve in the U.S. military. The condition can disrupt...